ITGAV
ENSG00000138448
Target class
Membrane receptor
Chromosome
2
Approved drugs
1
Clinical candidates (approved and in development)
9
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- Yes
- Other names
- CD51
- Target name
- ITGAV
- Gene name
- Integrin subunit alpha V
- Gene symbol
- ITGAV
- Protein name
- Integrin alpha-V (Vitronectin receptor) (Vitronectin receptor subunit alpha) (CD antigen CD51) [Cleaved into: Integrin alpha-V heavy chain; Integrin alpha-V light chain]
- VNRA
- MSK8
- VTNR
- Gene biotype
- Protein coding
- Gene family
- CD molecules|Integrin alpha subunits
- Target class
- Membrane receptor
- Target type
- Human gene
- Tissues expressed in
- 53
- Protein localisation evidence grade
- Approved
- Highest tissue expression
- 99.28
- Tissue specificity (Gini)
- 0.322
- Tissue specificity (tau)
- 0.691
- KEGG gene identifiers
- hsa:3685
- Protein interaction confidence
- 0.850404
- Protein interaction partners
- 99
- R-HSA-1236973
- R-HSA-1566948
- R-HSA-210990
- R-HSA-2129379
- R-HSA-216083
- R-HSA-2173789
- R-HSA-3000157
- R-HSA-3000170
- R-HSA-3000178
- R-HSA-4420097
- R-HSA-445144
- R-HSA-6798695
- R-HSA-9856532
- R-HSA-9860927
- End position
- 186680901
- Start position
- 186590010
- Chromosome
- 2
- Strand
- Forward
- Cell membrane
- Single-pass type I membrane protein. Cell junction, focal adhesion .
- Focal adhesion sites
Publication evidence
- PubMed 17158881
- Tissue specificity (tau)
- 0.691391
- Expression inequality (Gini)
- 0.322215
Expression in transcripts per million
- Artery - Aorta
- 99.28
- Cells - Cultured fibroblasts
- 77.66
- Artery - Coronary
- 77.05
- Artery - Tibial
- 76.87
- Ovary
- 58.07
Expression in transcripts per million
- Artery - Aorta99.28
- Cells - Cultured fibroblasts77.66
- Artery - Coronary77.05
- Artery - Tibial76.87
- Ovary58.07
- Uterus56.17
- Cervix - Ectocervix54.77
- Nerve - Tibial53.19
- Cervix - Endocervix52.33
- Thyroid47.74
- Lung46.61
- Brain - Spinal cord (cervical c-1)45.24
- Esophagus - Muscularis39.39
- Bladder37.44
- Adipose - Subcutaneous37.12
- Fallopian Tube37.09
- Adipose - Visceral (Omentum)35.26
- Esophagus - Gastroesophageal Junction35.21
- Adrenal Gland34.24
- Brain - Cerebellar Hemisphere32.43
- Breast - Mammary Tissue32.05
- Brain - Cerebellum31.24
- Colon - Sigmoid31.08
- Skin - Not Sun Exposed (Suprapubic)30.77
- Vagina30.01
And 29 more, listed on the interactive page.
- GO:0001525
- GO:0007155
- GO:0007160
- GO:0007229
- GO:0008284
- GO:0010745
- GO:0010888
- GO:0010989
- GO:0016477
- GO:0031589
- GO:0032369
- GO:0033627
- GO:0034113
- GO:0034446
- GO:0035987
- GO:0038027
- GO:0043277
- GO:0045785
- GO:0046718
- GO:0050748
- GO:0050764
- GO:0050919
- GO:0051057
- GO:0070588
- GO:1902533
And 2 more, listed on the interactive page.
- GO:0005886
- GO:0005925
- GO:0008305
- GO:0009986
- GO:0031258
- GO:0031527
- GO:0031528
- GO:0032587
- GO:0034683
- GO:0034684
- GO:0034685
- GO:0034686
- GO:0035579
- GO:0035867
- GO:0035868
- GO:0045335
- GO:0070062
- GO:0001968
- GO:0002020
- GO:0005178
- GO:0005515
- GO:0015026
- GO:0017134
- GO:0019960
- GO:0031994
- GO:0038132
- GO:0050840
- GO:1990430
Related records
Trials (105)
- A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
- A Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of 1.0 Mg Luminate® (Alg-1001) As A Treatment For Non-Exudative Macular Degeneration
- A Phase I Dose-Escalation Study of IMGN388 in Patients With Solid Tumors
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCI
- A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular Function
- A Safety And Efficacy Study Of Alg-1001 In Human Subjects With Symptomatic Focal Vitreomacular Adhesion
- A Safety And Efficacy Study Of ALG-1001 In Human Subjects With Wet Age-Related Macular Degeneration
- A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
- A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.
- A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary Angioplasty
- A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary Angioplasty
- A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)
- A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)
- A Study of EMD525797 in Solid Tumor Patients in Japan
- A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
- Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
- Abciximab for Prevention of Stroke Recurrence Before Endarterectomy in Symptomatic Carotid Stenosis
- Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI
- Abciximab i.v. Versus i.c. in ST-elevation Myocardial Infarction
Drugs (12)
- Abciximab Integrin alpha-V/beta-3 inhibitor
- Abituzumab Integrin alpha-V/beta-1 inhibitor
- ATN-161 Integrin alpha-V/beta-3 antagonist
- Bexotegrast
- Cilengitide Integrin alpha-V/beta-3 antagonist
- Etaracizumab Integrin alpha-V/beta-3 antagonist
- GSK-3008348 FREE BASE
- IMGN-388 Vitronectin receptor alpha binding agent
- Intetumumab Integrin alpha-V/beta-3 antagonist
- RG-7594 Integrin alpha-V/beta-1 binding agent
- Risuteganib
- STX-100 Integrin alpha-V/beta-6 inhibitor